Analysis of tumor cells from patients who developed resistance also revealed novel mutations in other RAS paralogs such as NRAS or HRAS as well as mutations in upstream activators including EGFR that can cause reactivation of wild‐type RAS paralogs [4, 8, 9, 10]. Here, EGFR is linked to neoplasm.